Literature DB >> 5944742

Topical epinephrine in glaucoma suspects.

B Becker, W R Morton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5944742     DOI: 10.1016/0002-9394(66)91483-8

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


× No keyword cloud information.
  8 in total

1.  Peripheral contrast sensitivity in glaucoma and ocular hypertension.

Authors:  F Falcão-Reis; E O'Donoghue; R Buceti; R A Hitchings; G B Arden
Journal:  Br J Ophthalmol       Date:  1990-12       Impact factor: 4.638

2.  Soluble forms of isobutylmethylxanthine enhance the ocular hypotension induced by catecholamines.

Authors:  M J Busch; P F Hoyng
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

3.  Levobunolol compared with timolol: a four-year study.

Authors:  O Geyer; M Lazar; G D Novack; D Shen; C Y Eto
Journal:  Br J Ophthalmol       Date:  1988-12       Impact factor: 4.638

Review 4.  Treating ocular hypertension to reduce glaucoma risk: when to treat?

Authors:  Eve J Higginbotham
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Does medical treatment of mild intraocular hypertension prevent glaucoma?

Authors:  I Aguinaga Ontoso; F Guillen Grima; E Aguinaga Ontoso; L R Fernandez Fernandez
Journal:  Eur J Epidemiol       Date:  1997-01       Impact factor: 8.082

6.  Timolol treatment prevents or delays glaucomatous visual field loss in individuals with ocular hypertension: a five-year, randomized, double-masked, clinical trial.

Authors:  M A Kass
Journal:  Trans Am Ophthalmol Soc       Date:  1989

7.  The optic disc in glaucoma. IV: Optic disc evaluation in the ocular hypertensive patient.

Authors:  R A Hitchings; C A Wheeler
Journal:  Br J Ophthalmol       Date:  1980-04       Impact factor: 4.638

8.  Cardiovascular effects of epinephrine and dipivalyl epinephrine applied topically to the eye in patients with glaucoma.

Authors:  C R Kerr; I Hass; S M Drance; M B Walters; M Schulzer
Journal:  Br J Ophthalmol       Date:  1982-02       Impact factor: 4.638

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.